Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06014697
Other study ID # 2023-3735
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 1, 2023
Est. completion date December 2023

Study information

Verified date October 2023
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The increasing incidence of actinic keratosis (AK), morbus Bowen (MB) and cutaneous squamous cell carcinoma (cSCC), the patients with often multiple lesions and the disadvantages of invasive diagnostics show the need for an accurate non-invasive diagnostic tool for the determination of invasive growth in AK and MB. Optical coherence tomography (OCT) is a non-invasive scanner creating cross-sectional images of the skin, to a depth of 1-1,5 mm based on light waves. Until now, OCT has been proposed as non-invasive diagnostic tool for basal cell carcinomas. Although the diagnostic value of OCT for detection and sub-typing of basal cell carcinomas has already been demonstrated, it is unclear whether OCT can discriminate between invasive and non-invasive lesions (AK, MB and cSCCs). There are some studies that describe OCT characteristics of AK, MB and cSCCs, however, these characteristics have a lot of overlap (8-13). To date there are no clearly distinctive OCT features to distinguish between AK, MB and cSCCs. This study aims to investigate the value of OCT in discriminating between the presence and absence of invasion in lesions with clinical suspicion for invasion. Two experienced OCT-assessors will evaluate the OCT scans independently. The OCT assessors are blinded to the histological diagnosis of the lesions (invasive or non-invasive), which is used as golden standard. A 5-point Likert scale is used for OCT assessment. 1. Definitely not invasive 2. Probably not invasive 3. Unknown, probably invasive/probably not invasive 4. Probably invasive 5. Definitely invasive In addition to completing the Likert-scale, assessors are asked to describe the presence/absence of predefined OCT characteristics (a.o. hyperkeratosis and the presence of the dermo-epidermal junction) In case of disagreement between the independent assessors, the OCT scan will be re-assessed in a consensus meeting.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 75
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients who are included in a previous study on OCT, with written informed consent to use their data regarding OCT. - Patients who retrospectively had an OCT scan for their skin lesion - With a histological confirmed actinic keratosis, bowens disease or cutaneous squamous cell carcinoma of the skin - with a differential diagnosis of a invasive lesion (cutaneous squamous cell carcinoma) and a non-invasive lesion (bowens disease or actinic keratosis). Exclusion Criteria: - patients who waived informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Optical Coherence Tomography
Assessment of the lesion with a non-invasive OCT scan according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
Other:
Clinical assessment
Clinical assessment of the lesion by a dermatologist according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)

Locations

Country Name City State
Netherlands Maastricht University Medical Center+ Maastricht

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

References & Publications (11)

Ahmady S, Jansen MHE, Nelemans PJ, Kessels JPHM, Arits AHMM, de Rooij MJM, Essers BAB, Quaedvlieg PJF, Kelleners-Smeets NWJ, Mosterd K. Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2022 Jun 1;158(6):634-640. doi: 10.1001/jamadermatol.2022.1034. — View Citation

Boone MA, Marneffe A, Suppa M, Miyamoto M, Alarcon I, Hofmann-Wellenhof R, Malvehy J, Pellacani G, Del Marmol V. High-definition optical coherence tomography algorithm for the discrimination of actinic keratosis from normal skin and from squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1606-15. doi: 10.1111/jdv.12954. Epub 2015 Feb 5. — View Citation

Friis KBE, Themstrup L, Jemec GBE. Optical coherence tomography in the diagnosis of actinic keratosis-A systematic review. Photodiagnosis Photodyn Ther. 2017 Jun;18:98-104. doi: 10.1016/j.pdpdt.2017.02.003. Epub 2017 Feb 7. — View Citation

Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989-2008. Eur J Cancer. 2012 Sep;48(13):2046-53. doi: 10.1016/j.ejca.2012.01.003. Epub 2012 Feb 16. — View Citation

Levine A, Wang K, Markowitz O. Optical Coherence Tomography in the Diagnosis of Skin Cancer. Dermatol Clin. 2017 Oct;35(4):465-488. doi: 10.1016/j.det.2017.06.008. Epub 2017 Aug 9. — View Citation

Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012 May;166(5):1069-80. doi: 10.1111/j.1365-2133.2012.10830.x. — View Citation

Marneffe A, Suppa M, Miyamoto M, Del Marmol V, Boone M. Validation of a diagnostic algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma by means of high-definition optical coherence tomography. Exp Dermatol. 2016 Sep;25(9):684-7. doi: 10.1111/exd.13036. — View Citation

Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):8-10. doi: 10.1067/mjd.2000.103343. — View Citation

Sattler E, Kastle R, Welzel J. Optical coherence tomography in dermatology. J Biomed Opt. 2013 Jun;18(6):061224. doi: 10.1117/1.JBO.18.6.061224. — View Citation

Sinx KAE, van Loo E, Tonk EHJ, Kelleners-Smeets NWJ, Winnepenninckx VJL, Nelemans PJ, Mosterd K. Optical Coherence Tomography for Noninvasive Diagnosis and Subtyping of Basal Cell Carcinoma: A Prospective Cohort Study. J Invest Dermatol. 2020 Oct;140(10):1962-1967. doi: 10.1016/j.jid.2020.01.034. Epub 2020 Mar 6. — View Citation

Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, Dreno B, Fargnoli MC, Forsea AM, Frenard C, Harwood CAlpha, Hauschild A, Hoeller C, Kandolf-Sekulovic L, Kaufmann R, Kelleners-Smeets NW, Malvehy J, Del Marmol V, Middleton MR, Moreno-Ramirez D, Pellecani G, Peris K, Saiag P, van den Beuken-van Everdingen MHJ, Vieira R, Zalaudek I, Eggermont AMM, Grob JJ; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer. 2020 Mar;128:60-82. doi: 10.1016/j.ejca.2020.01.007. Epub 2020 Feb 26. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity Sensitivity of OCT to detect invasion Through study completion, an average of 6 months
Primary Specificity Specificity of OCT in determining the presence/absence of invasion Through study completion, an average of 6 months
Secondary Negative predictive value Negative predictive value of OCT in determining the presence/absence of invasion Through study completion, an average of 6 months
Secondary Positive predictive value Positive predictive value of OCT in determining the presence/absence of invasion Through study completion, an average of 6 months
Secondary Area under the curve Area under the curve for OCT in determining the presence/absence of invasion Through study completion, an average of 6 months
Secondary Sensitivity of OCT features Sensitivity for specific OCT-features characteristic for the presence/absence of invasion, such as presence/absence of the dermo-epidermal junction or presence/absence of hyperkeratosis. Through study completion, an average of 6 months
Secondary Difference OCT and clinical practice Difference in diagnostic parameters (sensitivity, specificity and area under the curve) between OCT and clinical practice (clinical assessment). Through study completion, an average of 6 months
Secondary Specificity of OCT features Specificity for specific OCT-features characteristic for the presence/absence of invasion, such as presence/absence of the dermo-epidermal junction or presence/absence of hyperkeratosis. Through study completion, an average of 6 months
Secondary Positive predictive value of OCT features Positive predictive value for specific OCT-features characteristic for the presence/absence of invasion, such as presence/absence of the dermo-epidermal junction or presence/absence of hyperkeratosis. Through study completion, an average of 6 months
Secondary Negative predictive value of OCT features Negative predictive value for specific OCT-features characteristic for the presence/absence of invasion, such as presence/absence of the dermo-epidermal junction or presence/absence of hyperkeratosis. Through study completion, an average of 6 months
Secondary Area under the curve for OCT features Area under the curve for specific OCT-features characteristic for the presence/absence of invasion, such as presence/absence of the dermo-epidermal junction or presence/absence of hyperkeratosis. Through study completion, an average of 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05889312 - Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Completed NCT01194557 - Introducing Rapid Diagnostic Tests Into the Private Health Sector N/A
Completed NCT04257955 - COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer
Recruiting NCT05698212 - Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers Phase 2
Recruiting NCT03372330 - Peripheral Artery Disease and Sepsis Outcomes N/A
Active, not recruiting NCT06134011 - A Multi-omics-based Metabolic Typing Study of Gastric Cancer
Recruiting NCT06289803 - The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery N/A
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Not yet recruiting NCT05464576 - Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis N/A
Completed NCT06185127 - Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam During Bronchoscopy Phase 3
Recruiting NCT05824442 - Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis N/A
Not yet recruiting NCT06463223 - HIBOC = Hepatic Imaging Biomarkers in Obese Children
Not yet recruiting NCT06072820 - Analytical Evaluation of the Endotest® Diagnostic N/A
Recruiting NCT05587114 - Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood
Recruiting NCT06230458 - Fractional Exhaled Nitric Oxide (FeNO)- Test as add-on Test in the Diagnostic Work-up of Asthma N/A
Not yet recruiting NCT05948410 - How Does the Mood of the Patients Change Before and After the Invasive Urodynamic Study?
Not yet recruiting NCT05947565 - Patient Position and Invasive Urodynamic Study Results in Males N/A
Not yet recruiting NCT04490746 - Identifcation of Biomarkers for Active Pulmonary Tuberculosis
Completed NCT03381131 - Chinese Version of Fibromyalgia Criteria and Severity Scales Study